{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:43:46Z","timestamp":1780602226664,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40119-022-00257-7","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T06:24:54Z","timestamp":1646115894000},"page":"249-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-8495","authenticated-orcid":false,"given":"Anjali T.","family":"Owens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan B.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jipan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari S.","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar R.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"257_CR1","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu199","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733\u201379.","journal-title":"Eur Heart J"},{"key":"257_CR2","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76:e159-240.","journal-title":"J Am Coll Cardiol"},{"key":"257_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749\u201370.","journal-title":"Circ Res"},{"key":"257_CR4","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"58","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:e212\u201360.","journal-title":"J Am Coll Cardiol"},{"key":"257_CR5","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ejhf.541","volume":"18","author":"E Ammirati","year":"2016","unstructured":"Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18:1106\u201318.","journal-title":"Eur J Heart Fail"},{"key":"257_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary aArtery Risk Development in (Young) Adults. Circulation. 1995;92:785\u20139.","journal-title":"Circulation"},{"key":"257_CR7","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"257_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"SB Heitner","year":"2019","unstructured":"Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019;170:741\u20138.","journal-title":"Ann Intern Med"},{"key":"257_CR9","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232\u20139.","journal-title":"Circulation"},{"key":"257_CR10","doi-asserted-by":"publisher","first-page":"e006657","DOI":"10.1161\/JAHA.117.006657","volume":"7","author":"DY Lu","year":"2018","unstructured":"Lu DY, Pozios I, Haileselassie B, et al. Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. J Am Heart Assoc. 2018;7:e006657.","journal-title":"J Am Heart Assoc"},{"key":"257_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655\u201368.","journal-title":"N Engl J Med"},{"key":"257_CR12","doi-asserted-by":"publisher","first-page":"e007161","DOI":"10.1161\/JAHA.117.007161","volume":"6","author":"G Finocchiaro","year":"2017","unstructured":"Finocchiaro G, Magavern E, Sinagra G, et al. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy. J Am Heart Assoc. 2017;6:e007161.","journal-title":"J Am Heart Assoc"},{"key":"257_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/hrt.78.2.182","volume":"78","author":"S Cox","year":"1997","unstructured":"Cox S, O\u2019Donoghue AC, McKenna WJ, Steptoe A. Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart. 1997;78:182\u20137.","journal-title":"Heart"},{"key":"257_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11136-012-0182-y","volume":"22","author":"CM Huff","year":"2013","unstructured":"Huff CM, Turer AT, Wang A. Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy. Qual Life Res. 2013;22:647\u201352.","journal-title":"Qual Life Res"},{"key":"257_CR15","doi-asserted-by":"publisher","first-page":"e000488","DOI":"10.1136\/openhrt-2016-000488","volume":"3","author":"RC Luiten","year":"2016","unstructured":"Luiten RC, Ormond K, Post L, Asif IM, Wheeler MT, Caleshu C. Exercise restrictions trigger psychological difficulty in active and athletic adults with hypertrophic cardiomyopathy. Open Heart. 2016;3:e000488.","journal-title":"Open Heart"},{"key":"257_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12955-016-0467-x","volume":"14","author":"P Magnusson","year":"2016","unstructured":"Magnusson P, Morner S, Gadler F, Karlsson J. Health-related quality of life in hypertrophic cardiomyopathy patients with implantable defibrillators. Health Qual Life Outcomes. 2016;14:62.","journal-title":"Health Qual Life Outcomes"},{"key":"257_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/13696998.2021.1978242","volume":"24","author":"SS Jain","year":"2021","unstructured":"Jain SS, Li SS, Xie J, et al. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the US. J Med Econ. 2021;24:1115\u201323.","journal-title":"J Med Econ"},{"key":"257_CR18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","volume":"1","author":"LK Kim","year":"2016","unstructured":"Kim LK, Swaminathan RV, Looser P, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003\u20132011. JAMA Cardiol. 2016;1:324\u201332.","journal-title":"JAMA Cardiol"},{"key":"257_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jchf.2015.06.011","volume":"3","author":"M Liebregts","year":"2015","unstructured":"Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2015;3:896\u2013905.","journal-title":"JACC Heart Fail"},{"key":"257_CR20","unstructured":"Wells SB, Rowin E, Bhatt V, Maron M, Maron BJ. Racial differences in clinical course and outcome of patients with hypertrophic cardiomyopathy. Poster presented at ACC 2018; 10\u201312 March 2018; Orlando. Poster number 1238-091."},{"key":"257_CR21","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1093\/eurheartj\/eht150","volume":"34","author":"M Brignole","year":"2013","unstructured":"Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281\u2013329.","journal-title":"Eur Heart J"},{"key":"257_CR22","unstructured":"IBM Watson Health. IBM MarketScan Research Databases for Health Services Researchers [White Paper]. 2019. https:\/\/www.ibm.com\/downloads\/cas\/OWZWJ0QO. Accessed Dec 2021."},{"key":"257_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"257_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613\u20139.","journal-title":"J Clin Epidemiol"},{"key":"257_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3111\/13696998.2015.1041966","volume":"18","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Zhu Y, Fang Y, Ye W, McCollam P. Healthcare resource utilization and costs in working-age patients with high-risk atherosclerotic cardiovascular disease: findings from a multi-employer claims database. J Med Econ. 2015;18:655\u201365.","journal-title":"J Med Econ"},{"key":"257_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/1755-5922.12222","volume":"34","author":"E Yang","year":"2016","unstructured":"Yang E, Stokes M, Johansson S, et al. Clinical and economic outcomes among elderly myocardial infarction survivors in the USA. Cardiovasc Ther. 2016;34:450\u20139.","journal-title":"Cardiovasc Ther"},{"key":"257_CR27","first-page":"353","volume":"4","author":"J Kempf","year":"2011","unstructured":"Kempf J, Buysman E, Brixner D. Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting. Am Health Drug Benefits. 2011;4:353\u201361.","journal-title":"Am Health Drug Benefits"},{"key":"257_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jama.281.7.650","volume":"281","author":"BJ Maron","year":"1999","unstructured":"Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional US cohort. JAMA. 1999;281:650\u20135.","journal-title":"JAMA"},{"key":"257_CR29","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","volume":"34","author":"R Chowdhury","year":"2013","unstructured":"Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940\u20138.","journal-title":"Eur Heart J"},{"key":"257_CR30","first-page":"1","volume":"19","author":"S-T Chen","year":"2019","unstructured":"Chen S-T, Huang S-T, Shau W-Y, et al. Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan. BMC Cardiovasc Disord. 2019;19:1\u201313.","journal-title":"BMC Cardiovasc Disord"},{"key":"257_CR31","unstructured":"Sun D, Schaff HV, Houten HKV, et al. Health care utilization and costs of surgical septal myectomy and alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Presented at the Western Thoracic Surgical Association 46th Annual Meeting; 24\u201327 June 2020; Vail, Colorado. Abstract US2020."}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-022-00257-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-022-00257-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-022-00257-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T04:55:29Z","timestamp":1653540929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-022-00257-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["257"],"URL":"https:\/\/doi.org\/10.1007\/s40119-022-00257-7","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}